Glioblastoma D005909

Description

A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.   MeSH

Hierarchy View


Phase 4 Indicated Drugs (2)

Phase 2 Indicated Drugs (261)

Phase 1 Indicated Drugs (182)


Organization Involved with Phase 4 Indications (2)

Organization Involved with Phase 3 Indications (119)

Organization Involved with Phase 2 Indications (374)

Aadi, LLC

Aalborg University

Aarhus University

Accelerate Brain Cancer Cure

Acerta Pharma

Actuate Therapeutics Inc.

AEterna Zentaris

Agenus Inc.

Agouron

AiVita Biomedical, Inc.

Ajou University

Allegheny Health Network

All India Institute of Medical Sciences

American Board for Transplant Certification

American College of Radiology

Amgen

Angiochem Inc

AOP Orphan Pharmaceuticals AG

Apogenix GmbH

Arno Therapeutics

Arog Pharmaceuticals, Inc.

Array BioPharma

Assistance Publique - Hôpitaux de Paris

Atlantic Health System

Augusta University

Avid Bioservices

Axelar AB

Badalona Hospital Germans Trias i Pujol

Baptist Health

Barrow Neurological Institute

Basilea Pharmaceutica

Bayer

Baylor University

BeiGene

Beijing Tricision Biotherapeutics Inc

Ben Gurion University

Bhagwan Mahaveer Jain Hospital

BioMimetix Pharmaceutical, Inc.

Biotech Pharmaceutical Co., Ltd.

Boehringer Ingelheim

Boneca Corporation

Boston Biomedical

BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.

Brain Tumor Trials Collaborative

Brown University

BTG

Burzynski Research Institute

Caladrius Biosciences

Canadian Cancer Society

CANbridge Life Sciences Ltd.

CancerCare Manitoba

Cancer Research Institute

Cancer Research UK

Candel Therapeutics

Cantex Pharmaceuticals

Carlo Besta Neurological Institute

CarThera

Cascadian Therapeutics Inc.

Case Western Reserve University

CASI Pharmaceuticals, Inc.

Catholic University of Korea

Cellectar, Inc

Center for Neurosciences, Tucson

Centre Georges Francois Leclerc

Centre Jean Perrin

Cha Medical University

China Medical University

Chittaranjan National Cancer Institute

Chonnam National University

CHU Besançon

City of Hope National Medical Center

ClinDatrix, Inc.

Clinica Universidad de Navarra

Clinique Neuro-Outaouais

Columbia University

Cooperative Trials Group for Neuro-Oncology

Cortice Biosciences, Inc.

Covance

Cure Brain Cancer Foundation, Australia

Cure&Sure Biotech Co., LTD

CytoVac A/S

CytRx

Dartmouth University

Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan

Denovo BioPharma

Dent Neurologic Institute

Deutsche Krebshilfe e.V.

Developmental Therapeutics Consortium

Direct Therapeutics

Diverse Biotech

DNAtrix, Inc.

DUSA Pharmaceuticals

Eastern Cooperative Oncology Group

ECCO - the European CanCer Organisation

Eisai

Emory University

Enterome

Epitopoietic Research Corporation

Essex Pharma

Ever Supreme Bio Technology Co., Ltd.

Exelixis

Feinstein Institute for Medical Research

Flinders University

Florida Cancer Specialists, Sarasota

Fondation ARC

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Forma Therapeutics, Inc.

Free University of Brussels

Gan and Lee Pharmaceuticals, USA

Gateway for Cancer Research

Geisinger Clinic

Genenta Science S.R.L.

Genentech

Genexine, Inc.

German Cancer Research Center

German Federal Ministry of Education and Research

Gilead Sciences

GlaxoSmithKline

Government of Canada

Government of Taiwan

Guangxi Medical University

Guangzhou Medical University

Guangzhou Trinomab Biotech Co., Ltd.

Guilin Medical University

Gujarat Cancer & Research Institute

GW Research

Hacettepe University

Hangzhou Normal University

Hebrew University

Heidelberg Clinical Research Centre

Hengrui Therapeutics, Inc.

Henry Ford Health System

Hoag Memorial Hospital Presbyterian

Huazhong University of Science and Technology

Huzhou University

Icad, Inc.

Icahn School of Medicine at Mount Sinai

I-Mab Biopharma

Imclone

immatics Biotechnologies GmbH

Immunomedics

Imvax

Incheon St.Mary's Hospital

Incyte

Indiana University

Inovio Pharmaceuticals

InSightec

Inspyr Therapeutics, Inc.

Institut Gustave Roussy

Institut National de la Santé Et de la Recherche Médicale, France

Istari Oncology, Inc.

Istituto Nazionale per lo Studio e la Cura dei Tumori

Istituto Oncologico Veneto IRCCS

James Graham Brown Cancer Center

Janssen Pharmaceutica NV

Jaslok Hospital and Research Centre, Mumbai, India

Jinan University

Johns Hopkins University

Johnson and Johnson

John Wayne Cancer Institute

Julius-Maximilians University

Kadmon

Karyopharm Therapeutics Inc

Kazia Therapeutics Limited

Kepler University

Keryx

King Fahad Medical City

Konkuk University

Lantheus Medical Imaging

Lantmannen Medical AB

Lenox Hill Hospital

LifePhotonic GmbH

Light Sciences Oncology

Lipodom Therapeutics

Lipopharma Therapeutics SL

London Vaccination Clinic

Ludwig Institute for Cancer Research

Maastricht University

Mario Negri Institute

Marmara University

Marnie Rose Foundation

Mayo Clinic

Medac

Medical Cannabis Bike Tour

Medical College of Wisconsin

Medical Research Council

Medical University Innsbruck

Medical University of South Carolina

Medicenna Therapeutics, Inc.

MediciNova

MediGene

MedImmune

Memorial Hermann Health System

Memorial Sloan-Kettering Cancer Center

Merrimack Pharmaceuticals

Methodist Cancer Center, Houston, Texas

Methodist Healthcare

MetVital, Inc.

Millennium Pharmaceuticals

Millennix

Monteris Medical

MultiCare Health System Research Institute

Musli Thyropeutics Ltd.

Myrexis Inc.

Nanchang University

Nanxishan Hospital of Guangxi Zhuang Autonomous Region

National Cancer Center, Korea

National Cancer Institute, France

National Comprehensive Cancer Network

National Health and Medical Research Council, Australia

National Health Service, United Kingdom

National Institutes of Health (NIH)

NCRI Clinical Studies Groups

Nektar Therapeutics

NeOnc Technologies

NeuGATE Theranostics

Neurocrine Biosciences

Neurological Surgery, P.C.

Newcastle University

NewLink Genetics Inc

New York University

Ningbo Yinzhou People's Hospital

Nobel Pharmaceuticals

North Central Cancer Treatment Group

Northern Sydney and Central Coast Area Health Service

Northwell Health

Northwestern University

Novacea

Noxxon AG

NuvOx Pharma Pty Ltd

NX PharmaGen

Oakland University

Oblato, Inc.

Ohio State University

OHSU Knight Cancer Institute

Olympion Medical Center

Oncoceutics, Inc.

OncoEthix

Oncovir, Inc.

Oryx GmbH & Co. KG

Osaka Medical College

Osaka University

OSI Pharmaceuticals

Pediatric Brain Tumor Consortium

Peninsula Health

Pennsylvania State University

PharmAbcine

Philogen S.p.A.

photonamic GmbH & Co. KG

PIQUR Therapeutics AG

Plexxikon

Progenics

Puma Biotechnology, Inc.

Regina Elena Cancer Institute

Region Skane

Rhode Island Hospital

RTOG Foundation

Rush University

Rutgers University

Saint John's Cancer Institute

Saitama Medical University

Sanofi

SCRI Development Innovations

Seoul National University

Shandong University

Shenzhen Geno-Immune Medical Institute

Sophiris Bio Corp

Sorbonne University

Specialized Medical Services, Oncology BV

Spectrum Pharmaceuticals

Sponsor GmbH

Stanford University

State University of New York, Buffalo

Stemcentrx

Stemline Therapeutics, Inc.

St. Joseph's Hospital and Medical Center - Phoenix, Arizona

Sumitomo Dainippon

Sungkyunkwan University

Symphogen A/S

SynerGene Therapeutics, Inc.

Technion University

Temple University

Tesaro

Teva

Thallion Pharmaceuticals

The Christie NHS Foundation Trust

The Cleveland Clinic

The Guthrie Clinic

Theradis pharma

The University of Texas, Dallas

Thomas Jefferson University

Tilray

Tracon Pharmaceuticals Inc.

Transgene

Translational Research Informatics Center, Kobe, Hyogo, Japan

Translational Research in Oncology

TransMolecular

Treovir, LLC

Triphase Research and Development Corporation

Tufts University

TVAX Biomedical

UNICANCER

Universidad Complutense de Madrid

Universitair Ziekenhuis Brussel

Université catholique de Louvain

University Hospital Heidelberg

University Hospital of North Norway

University of Alabama, Birmingham

University of Antwerp

University of Arizona

University of Bergen

University of Bern

University of Bordeaux

University of Brescia

University of Bristol

University of California, Davis

University of California, Irvine

University of California, San Diego

University of Cambridge

University of Chicago

University of Cincinnati

University of Colorado, Denver

University of Copenhagen

University of Eastern Finland

University of Florida

University of Franche-Comté

University of Geneva

University of Glasgow

University of Groningen

University of Helsinki

University of Hull

University of Ioannina

University of Iowa

University of Kentucky

University of Leeds

University of Liverpool

University of London

University of Lorraine

University of Louisville

University of Malaga

University of Maryland

University of Massachusetts

University of Miami

University of Michigan

University of Munster

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Padova

University of Pennsylvania

University of Pittsburgh

University of Regensburg

University of Rochester

University of Sherbrooke

University of South Carolina

University of Southern Denmark

University of Sydney

University of Texas, San Antonio

University of Ulm

University of Ulsan

University of Virginia

Upsher-Smith Laboratories

Vanderbilt University

Vaximm GmbH

Virginia Commonwealth University

Voices Against Brain Cancer

Wake Forest University

Washington University in St. Louis

Wayne State University

Wyeth

Xoft, Inc.

Yale University

Yonsei University

Zhejiang University

Ziopharm

Organization Involved with Phase 1 Indications (96)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.